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RESEARCH IN CONTEXT 
Evidence before this study: 
Numerous studies have provided evidence regarding the applications of fractional exhaled 
nitric oxide (FeNO) measurements in the clinical management of asthma. To identify studies 
in which FeNO was used in patients with non-specific respiratory symptoms we searched 
PubMed up until 1st January 2015 for randomised controlled trials which investigated the 
association between fractional exhaled nitric oxide (FeNO) and response to inhaled or oral 
steroids in patients with unclear asthma, using search terms: “feno”, “asthma”, (“chronic 
respiratory symptoms” OR “unspecific respiratory symptoms” OR “undiagnosed asthma” OR 
“non-specific respiratory symptoms”) and (“steroids” OR “corticosteroids”). The majority of 
trials were excluded for not evaluating the required association. In the trial by Smith et al, in 
patients with undiagnosed respiratory symptoms, the group with the highest FeNO (>47 ppb) 
demonstrated a significantly greater response to four weeks of inhaled corticosteroids (ICS) 
in all outcomes. A recent study in patients with confirmed asthma, by Malinovschi et al, found 
that FeNO levels were associated with improved asthma control after ICS treatment in patients 
with intermediate (≥25 and <50 ppb) and high FeNO (≥50 ppb), compared to normal levels 
(<25 ppb). 
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Added value of this study 
The previous trial of FeNO in a non-specific respiratory symptoms (NSRS) patient population 
has weaknesses mainly due to the relatively small sample size (n=52) and study design 
(single-blind, fixed-sequence design with placebo period followed by treatment period). To our 
knowledge, the current trial is the largest randomised placebo-controlled trial using FeNO in 
an NSRS patient population to date, and therefore offers well-powered evidence. The NSRS 
population assessed in this trial is a difficult-to-manage patient population with insignificant 
bronchodilator reversibility. The results were consistent with previous findings in both asthma 
and undiagnosed asthma, with a clear association between high FeNO and a greater 
likelihood to respond to inhaled corticosteroids. 
Implications of all the available evidence 
This study provides strong support for the use of FeNO measurement in primary care, to 
inform ICS prescribing decisions in patients with non-specific respiratory symptoms, unclear 
asthma and insignificant bronchodilator reversibility. This data supports a targeted 
individualised approach in the clinical management of chronic airway diseases.  
ABSTRACT 
Background:  
Chronic non-specific respiratory symptoms (NSRS) are difficult to manage. This trial evaluated 
the association between FeNO and the response to Inhaled corticosteroids (ICS) in NSRS 
patients. 
Methods: A double-blind randomised controlled trial in undiagnosed patients, aged 18-80, 
with cough, wheeze and/or dyspnoea and <20% bronchodilator reversibility, 4-week treatment 
period with ICS (QVAR 80 mcg, two puffs twice per day, equivalent to 400 mcg 
beclomethasone dipropionate) or placebo. Stratified randomisation was carried out within 
categories of baseline FeNO – normal (≤25 ppb), intermediate (>25 - <40 ppb), and high (≥40 
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ppb) - allocation. Generalised linear modelling assessed FeNO as a predictor of response, 
estimating an interaction effect between FeNO and treatment, on change in ACQ7. Logistic 
regression assessed FeNO and clinical opinion of asthma status as predictors of response. 
Findings: 294 patients were randomised (148 ICS, 146 placebo). Following exclusions due 
to protocol violations 214 patients were analysed (114 ICS, 100 placebo). Treatment effects 
were significant for high FeNO (mean change in ACQ7, 0.49 [95% CI, 0.14, 0.84]), non-
significant for normal and intermediate FeNO (0.10 [95% CI, -0.24, 0.44] and 0.25 [-0.10, 0.61]: 
P=0.044 for interaction). FeNO > 50 ppb was associated with greater odds of improvement in 
cough on the visual analogue scale (odds ratio, 2.37 [1.01, 5.55]), while an affirmative clinical 
opinion of asthma was not predictive (0.92 [0.47,1.82]). This study is registered on 
ClinicalTrials.gov (number: NCT02294279). 
Interpretation: FeNO may predict response to ICS in patients with NSRS, while clinical 
opinion is not predictive. 
Funding: Partially funded by Circassia, formerly Aerocrine. 
INTRODUCTION 
The European Asthma Research and Innovation Partnership rated asthma diagnosis as the 
most important area requiring further research.(1) Respiratory symptoms including cough and 
breathlessness are a common presentation in the primary care setting, and can be difficult to 
manage(2) - particularly when symptoms are non-specific. Treatment decisions are even more 
difficult if the potential diagnosis is not supported by typical criteria, e.g. patient has suspected 
asthma but does not show reversibility to short-acting beta agonists (SABA). Such symptom 
patterns, as well as unexplained chronic cough, cause significant impairments in quality of life. 
Effective assessment and treatment approaches are needed.(3)  
Inhaled corticosteroids (ICS) are often prescribed, however, the response to ICS varies widely 
within patients with confirmed asthma,(4) which may also be the case for patients with 
respiratory symptoms without clear asthma. Identifying patients most likely to respond to ICS 
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would minimise inappropriate treatment and limit side effects and unnecessary healthcare 
costs. (5, 6)One potential strategy to target this problem is to assess fractional exhaled nitric 
oxide (FeNO) in addition to the current standard of care when informing ICS prescribing 
decisions. FeNO has been identified as a marker for type-2 allergic airway inflammation(7) in 
patients with asthma,(8) and has been shown to be a reliable predictor of responsiveness to 
ICS in patients with asthma.(8-11) A type-2 pattern of airway inflammation, involving lymphoid 
cells, T-helper 2 cells, tissue eosinophilia, and IgE production, (12) may be evident in patients 
without an established asthma diagnosis, opening the potential for FeNO-guided treatment in 
this population. On this strategy, clinical guidelines are divided: NICE recommends FeNO 
measurement to guide diagnosis and management of asthma, (13) while GINA states that 
FeNO cannot yet be recommended, based on the current body of evidence.(14) While this 
inconsistent guidance exists for patients with asthma, due to limited evidence, there is even 
less data for patients without clear asthma.  
Among the limited evidence in the population without a clear asthma diagnosis, one study 
found that an elevated baseline FeNO level (>47 ppb) in patients with previously undiagnosed 
respiratory symptoms was predictive of an ICS response. In this study, steroid response was 
defined as change in symptoms, peak flows, spirometry, or airway hyperresponsiveness to 
adenosine based on established guidelines and recommendation.(15) However, this was a 
small, single-blind study and these results alone are not entirely persuasive. 
Clinicians rely on a range of measures including FeNO, spirometry, blood eosinophils and 
their own clinical judgement when assessing patients but there is little information on what is 
most useful in guiding ICS treatment in patients with undiagnosed respiratory symptoms. To 
this end we carried out a randomised placebo-controlled trial to investigate the value of FeNO, 
and other baseline measurements, in predicting a clinical response to 4-weeks of treatment 
with ICS, in a sample of patients with non-specific respiratory symptoms without asthma and 
insignificant bronchodilator reversibility.  
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METHODS 
Study design 
This was a six-week randomised, multi-centre, double-blind, placebo-controlled study, at 
primary care centres and hospital sites in the UK and Singapore. Patient enrolment began on 
the 4th of February 2015 with the last patient completing the study on the 26th August 2016. 
The study consisted of a two-week assessment period, for screening and measurement of 
baseline variables, followed by a four-week treatment period. Participants were randomised 
at the end of the assessment period, to either the treatment arm (extrafine ICS - QVAR 80 
mcg Inhalation Aerosol, two puffs twice per day, equivalent to standard 400 mcg 
beclomethasone dipropionate) or the control arm (placebo – same regimen of two puffs twice 
per day, with inactive ingredient). The active study drug and matching placebo were provided 
by TEVA RESPIRATORY, LLC Teva Pharmaceuticals Europe BV, Piet Heinkade 107, 1019 
GM Amsterdam, the Netherlands. The study sample population consisted of patients (aged 
18-80 years) with non-specific, persistent respiratory symptoms (cough and/or wheeze and/or 
chronic dyspnoea for ≥ 6 weeks before screening), with no previous diagnosis of asthma.  
If patients displayed a forced expiratory volume in the first second (FEV1) < 90% predicted at 
screening, they also needed to show an insignificant reversibility predefined as FEV1 <20% to 
short-acting beta-agonists (SABA) at visit 1 or within the previous year. Subjects who were 
ever diagnosed with asthma or any other significant chronic respiratory disease, and/or who 
had received treatment with oral, inhaled or systemic corticosteroids, a leukotriene modifier or 
long-acting beta agonist within four weeks prior to the first study visit, were excluded. The full 
study inclusion and exclusion criteria can be found in Supplementary table 1.  
The primary objective was to determine whether the response to treatment (extrafine ICS) 
varies between FeNO groups by considering the change in ACQ scores from baseline to 
follow-up. For this objective, response to treatment was measured in terms of change in 
Asthma Control Questionnaire (ACQ7) from baseline.  The ACQ7 was selected as there is 
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no appropriate endpoint for patients with non-specific respiratory symptoms. The steering 
committee chose the ACQ7 a priori as this was believed to be the closest response 
assessment to date for this patient population. Management of NSRS patients in routine 
clinical care is similar to the management of patients suspected for asthma, therefore a 
pragmatic study approach was adopted to reflect real-life clinical care. 
The secondary objectives were to investigate the relationship between FeNO and treatment 
response, in terms of changes from baseline in symptom and cough severity scores (each 
measured in millimetres on a visual analogue scale [VAS]), and changes in spirometry 
measurements. The first exploratory objective was to investigate interaction effects between 
FeNO and treatment arm, on the following endpoints: Global Evaluation of Treatment 
Effectiveness (GETE) scale (16) and EuroQol 5 Dimensions Questionnaire (EQ-5D-3L).(17) 
The second exploratory objective was to evaluate the following factors as predictors of 
clinical response; FeNO, spirometry, peripheral blood eosinophil count and clinical 
judgement of asthma diagnosis. For this objective, clinical responses to treatment were 
defined in two ways - as a decrease in ACQ7 ≥0.5, and a decrease in visual cough score of 
≥ 20 mm.  
The study and all amendments were approved by the National Research Ethics Service 
Committee Yorkshire & the Humber – South Yorkshire (14/YH/0129), for UK sites. For 
Singapore sites, the study was approved by the Parkway Independent Ethics Committee 
(PIEC/2014/028) and SingHealth Centralised Institutional Review Board (CIRB/2014/2052). 
This study is registered on ClinicalTrials.gov (NCT02294279) and on the Health Research 
Authority NHS register (Eudract number 2014-000051-90).  The study was conducted in full 
accordance with the International Conference on Harmonisation (ICH) Good Clinical Practice 
(GCP) Consolidated Guideline (E6) requirements of the ICH E2D guideline (Post-Approval 
Safety Data Management: Definitions and Standards for Expedited Reporting), the principles 
of the Declaration of Helsinki and the EU Clinical Trials Directive (2001/20/EC) as well as 
with any other applicable national and local laws and regulations. 
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Study procedures 
Three visits were involved in the study procedures: visit 1, during which patients were 
screened according to study criteria and invited to participate; visit 2, during which eligibility 
for further study participation was confirmed and patients were randomised to ICS or placebo, 
and; visit 3 (end of study visit), after the four-week treatment period, during which the final 
outcome measurements were assessed. Supplementary table 2 provides details of study 
procedures and assessments. The two-week assessment period (between visits 1 and 2) had 
a window of +/- 7 days and the four-week treatment period had a window of +/-2 days (between 
visits 2 and 3). At visit 1, baseline measurements were performed for eligible participants, 
including: FeNO (measured using NIOX VERO [Circassia]); Asthma Control Questionnaire 
(ACQ7); perception of asthma symptoms measured on a 0-100 horizontal visual analogue 
scale (VAS Symptom), where 0 is not bothersome at all and 100 is extremely bothersome; 
severity of cough measured on a 0-100 vertical visual analogue scale (VAS Cough), where 0 
is no cough and 100 is worse cough ever; FEV1; FEV1 % predicted; forced vital capacity (FVC); 
FVC% predicted; FEV1/FVC; peak expiratory flow (PEF); peripheral blood eosinophils (count 
x 109/L); GETE, and; EQ-5D-3L. In addition, the patients’ clinicians were asked to give a yes 
or no response to the question, “In your clinical opinion, is the patient asthmatic?”. 
At visit 2, patients were asked if their non-specific respiratory symptoms had persisted since 
the previous visit. If symptoms were not persistent, the patient was excluded. Patients were 
asked about medications taken between visit 1 and visit 2: if any were prohibited medications 
for the study (oral, inhaled or systemic corticosteroids, leukotriene modifiers, or long-acting 
beta agonists), the patient was excluded. Finally, patients were asked if they experienced any 
adverse events between visit 1 and visit 2 (before receiving the study drug or placebo): the 
patient was excluded if they experienced one or more adverse events. 
Following confirmation of informed consent by eligible participants, stratified randomisation 
was carried out, within predefined categories of baseline FeNO (normal, ≤25 ppb; 
intermediate, >25 - <40 ppb; high, ≥40 ppb).(15, 18)  
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Block randomisation was performed by in-house software using blocks of size 6 with a 1:1 
ratio of active to placebo and were stratified by FeNO category. The system kept track of all 
kit numbers and respective status, whenever randomisation request was made the 
appropriate kit number was delivered to end user. All the information was concealed securely 
in a server and none of the study team had access to it. All data was captured electronically, 
using the Enterprise system of OpenClinica software.(19) Unblinding was performed after data 
quality checks and database lock and once primary and secondary analyses were complete. 
Study endpoints 
The primary endpoint was to analyse the interaction between baseline FeNO and the 
treatment effect in ACQ change compared to placebo. The primary comparison was the overall 
interaction between treatment groups to understand if FeNO levels among treatment groups 
can modify the change in ACQ7 score. Interaction analysis was used to determine whether 
the effect or, more specifically, the response to the treatment, varies between the FeNO 
groups.  
Secondary endpoints, for which interaction effects were also estimated, included changes in: 
VAS Symptoms; VAS Cough, and; lung function (FEV1, FEV1 % predicted, FVC, FVC % 
predicted, PEF). Exploratory endpoints included changes from baseline in GETE and EQ-5D-
3L. 
Statistical analysis 
A Per-Protocol set, in which all primary and secondary analyses were carried out, was 
prepared by applying the following exclusions to the randomised study sample: non-
completion of the primary endpoint; non-compliance to treatment (ascertained by patient 
report), and study visits made outside the predefined visit windows. A Main-Analysis set was 
also created, where the study window exclusion criteria was not applied. 
Based on 80% power for detecting a treatment/FeNO interaction effect in the primary analysis, 
a required sample size of 264 patients was computed. Baseline summary statistics were 
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computed and compared between treatment arms, using Mann-Whitney and chi-square tests. 
The primary analysis used Generalised Linear Models to estimate the treatment effects, in 
terms of change in ACQ7, in each of the three baseline FeNO categories. An interaction was 
then tested, between treatment arm and baseline FeNO, on change in ACQ7 and ACQ6. This 
was done using another Generalised Linear Model, with FeNO centred on the mean. The 
coefficient of the interaction effect was obtained from the model, with 95% confidence intervals 
(CI). The interaction effect was interpreted as the change in treatment effect on the outcome 
when baseline FeNO increases. Similar models were repeated to estimate interaction effects 
on the secondary and exploratory endpoints. In all models, there was adjustment by smoking 
status (a potential confounder). A multiple linear regression was undertaken to evaluate the 
difference in gradients. The covariates added in this model will include the baseline value of 
the ACQ7 score. 
In the Main Analysis set (and in the extrafine ICS arm only), predictors of clinical response to 
treatment were investigated, in terms of ACQ7 (decrease ≥0.5) and VAS Cough (decrease ≥ 
20 mm). Potential predictors were tested in univariable logistic regression models and, if 
statistically significant and routinely taken in clinical practice, were included in a multivariable 
model which included baseline FeNO as a covariate.  
All statistical analyses were performed using SAS version 9.3.(20) 
Role of funding source 
This was an investigator-initiated trial, with Prof David B Price as Chief Scientist and 
Observational & Pragmatic Research Institute as the sponsor. Partial study funding was 
provided by Circassia, formerly Aerocrine, in the form of an unrestricted grant. Circassia 
provided NIOX machines for FeNO measurement on loan for the duration of the trial. Circassia 
did not contribute to the trial in any other way: there was no involvement in the trial design or 
execution of the trial such as data collection, analysis or interpretation of the data, or any 
aspect pertinent to the trial or the content of the manuscript. In addition, TEVA 
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Pharmaceuticals did not provide funding, but provided the study drugs, QVAR and matching 
placebo. TEVA did not contribute to the trial in any other way: there was no involvement in the 
trial design or execution of the trial such as data collection, analysis or interpretation of the 
data, or any aspect pertinent to the trial or the content of the manuscript. 
RESULTS 
Patients  
Of the 517 patients screened at 26 UK primary care centres and 3 Singapore centres, 294 
patients were randomised after applying inclusion and exclusion criteria; 148 to the extrafine 
ICS arm and 146 to the placebo arm. Following exclusions for non-completion of the primary 
endpoint and non-compliance to treatment, 259 patients were included in the Main-Analysis   
set. Following further exclusions for protocol violation, the Per-Protocol (PP) set consisted of 
214 patients - 114 in the extrafine ICS arm and 100 in the placebo arm (Figure 1). The main 
reason for ineligibility to the PP set was that the study visits were outside the study window. 
In the Per-Protocol set, mean ages were 50.0 (standard deviation [SD], 15.5) and 47.7 years 
(SD, 17.0) in the extrafine ICS and placebo arms, respectively; over half of the sample were 
women, and 73/114 = 64.0% and 73/100 = 73.0% were non-smokers, in the extrafine ICS and 
placebo arms, respectively (Table 1). The proportions of patients predicted to be asthmatic by 
clinicians were 62/114 = 54.9% in the extrafine ICS arm and 60/100 = 60.0% in the placebo 
arm. Patients in whom reversibility was determined at baseline, mean scores (computed as 
difference in FEV1 before and after salbutamol multiplied by 100) were 2.37% (SD, 0.84) and 
2.47% (SD, 0.74) in the extrafine ICS and placebo arms, respectively. Only 4 patients (2 in 
the extrafine ICS arm and 2 in the placebo arm) were active or ex-smokers and had spirometry 
values that would meet a COPD diagnosis. Baseline characteristics by FeNO category can be 
found in Supplementary table 3. Approximately 40% of patients reported all three symptoms 
of cough, dyspnoea and wheeze. Cough was the most prevalent symptom, reported by over 
80% of patients.  The majority of patients had an FEV1% predicted more than 90% (63/114 
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=55.3% in the ICS group and 63/100=63% in the placebo group) and those with less than 
90%, 5/88=5.7% had  15% FEV1 reversibility (Supplementary table 4).  
Primary analysis 
We observed a significant interaction between baseline FeNO and treatment arm (0.071 (95% 
CI, 0.002, 0.139)), suggesting the size of treatment response depended on the level of FeNO. 
For every 10ppb increase in baseline FeNO, the change in ACQ7 was 0.071 greater in the 
extrafine ICS arm compared to the placebo arm (Table 2). From baseline to the end of 
treatment period, ACQ7 improved by 0.29 (95% CI, 0.08-0.49) in the extrafine ICS arm 
compared with the placebo arm. This association was adjusted by baseline FeNO and 
smoking status. Within baseline FeNO categories, the adjusted treatment effect was 
statistically significant and clinically relevant in the high FeNO category (≥40 ppb), with a mean 
change in ACQ7 of 0.49 (95% CI; 0.14, 0.84), with no statistically significant treatment effects 
in the normal (≤25 ppb) (0.10 (95% CI, -0.24, 0.44)) and intermediate (>25 - <40 ppb) (0.25 
(95% CI, -0.10, 0.61)) FeNO categories. This was also found when ATS FeNO categorisation 
was used (Supplementary table 5). The sensitivity analysis further strengthened the 
association between FeNO and the treatment arm. There was a significant improvement in 
outcome as FeNO decreases for extrafine ICS compared to placebo prescribed patients 
(p=0.024) (Table 2). 
The number of patients showing a clinically important change with ACQ (≥0.5) was higher in 
patients receiving ICS (80/114 = 70.2%) treatment compared to those taking placebo 
(58/100=58.0%) (Table 3).  
The interaction between baseline FeNO and treatment arm when ACQ6 was used, was similar 
to that seen with the ACQ7 (Table 4, Supplementary figure 1). Stratification of the ACQ6 score 
by FeNO levels found a positive association in the higher FeNO group between ACQ6 and 
treatment group 0.53 (95% CI, 0.12 – 0.93) (Supplementary table 6). There was a decrease 
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in the outcome value of ACQ6 in the ICS group compared with the placebo group after 
adjustment for smoking and baseline value (0.076 (95% CI, -0.004, 0.155)) (Table 4).  
Secondary analyses 
There were significant interactions between baseline FeNO and treatment arm, in terms of 
change in VAS Cough (3.406 (95% CI, 0.707, 6.105)) and FEV1 (0.021 (95% CI, 0.005, 0.036)) 
(Table 5). For the remaining spirometry measurements and for VAS Symptom, the interaction 
effects were not significant (Table 5).  
Exploratory analysis 
The interaction effects for the exploratory endpoints can be seen in Supplementary table 7. In 
these analyses, there was a significant interaction effect for change in GETE (OR 4.004 (95% 
CI, 1.623, 9.876)), but not for EQ-5D-3L (OR 0.999 (95% CI, 0.990, 1.008)). 
Of the baseline measurements tested in prediction models, only a report of no additional 
treatment being taken for their non-specific respiratory symptoms at study enrolment was 
associated with clinical improvement of ACQ7 (decrease ≥0.5), in patients receiving extrafine 
ICS. Those who did not have additional treatments were over twice as likely to show clinical 
improvement in ACQ7 compared to those who did (OR, 2.22; 95% CI, 1.06-4.76) (Figure 2). 
In the model for clinical improvement in cough (defined as a VAS decrease ≥ 20 mm), the 
following baseline measures were significantly predictive in unadjusted models: FeNO 
(continuous and binary [>50 ppb]), blood eosinophil count and report of dyspnoea symptoms. 
In the best adjusted model, dyspnoea and FeNO were retained as significant predictors. For 
every 10ppb increase in baseline FeNO, the odds-ratio of clinical improvement in VAS cough 
was 1.17 (95% CI; 1.02-1.34) (Figure 2). We observed a positive correlation between 
improvement in FeNO and ACQ7 scores, EuroQol-5, FEV1 and VAS cough (Supplementary 
figure 2). 
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Increasing blood eosinophil counts showed a similar trend for improvement in VAS cough or 
ACQ7 score as did increasing FeNO levels (Supplementary figure 3 and 4). 
A summary of adverse events during the study can be found in Table 6. 
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DISCUSSION 
This was a double-blind randomised controlled trial to explore the utility of FeNO in predicting 
response to four weeks of treatment with inhaled corticosteroids in patients with undiagnosed, 
non-specific respiratory symptoms. A higher baseline FeNO was associated with a greater 
likelihood of a positive response to ICS in terms of ACQ7, severity of cough, FEV1 and GETE. 
The exploratory analysis found that baseline FeNO was a better predictor of clinical 
improvement in VAS Cough (≥ 20mm) than peripheral blood eosinophils, and that neither 
FEV1 % predicted nor clinical opinion of asthma were associated with response to treatment. 
These findings build on previous evidence of the utility of FeNO in asthma trials, as well as 
the limited evidence observed in patients with non-specific respiratory symptoms. In particular, 
a similar study by Smith et al (15), with a fixed-sequence design rather than parallel arms, also 
observed associations between baseline FeNO and response to ICS in patients with 
undiagnosed respiratory symptoms. In this trial, a cut-off for FeNO of >47 ppb was associated 
with a predefined minimum increase in FEV1 of 12% or more. However, the limitations of this 
study were the small patient number (n=52), the single-blind design, fixed-sequence design 
with a placebo period followed by treatment.  
In the current study, we observed a statistically significant improvement in ACQ7, which 
reached clinical significance in patients with a high FeNO signal (≥40 ppb). Among patients 
with non-specific respiratory symptoms, high FeNO levels were able to identify ICS responsive 
patients. An observational study by Martin et al also reported that FeNO readings were 
accurate at predicting patient response to ICS.(21) Our data complement these findings using 
a larger study population further supporting the use of FeNO measurement in patients with 
non-specific respiratory symptoms potentially responsive to ICS therapy. This would avoid the 
prescription of unnecessary ICS therapy in patients with low FeNO who are unlikely to benefit 
from this treatment, and encourage further investigation of the symptoms ensuring more 
accurate and effective diagnosis and treatment. This finding was further strengthened by the 
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statistically significant interaction effect seen between FeNO and ICS treatment. For every 
10ppb increase in baseline FeNO, the change in ACQ7 from baseline was 0.071 (95% CI, 
(0.002, 0.139) greater in those treated with ICS compared to placebo  
FeNO also had a strong association with improvement in cough severity. Higher FeNO values 
were associated with significantly greater odds of a clinical response defined as an 
improvement of ≥ 20 mm on the visual analogue scale for cough symptoms. In this trial, the 
improvement of 20mm or more exceeds the minimal important difference suggested in the 
literature.(22) We observed that patients who did not take any additional therapies for their 
non-specific respiratory symptoms at study enrolment and who were randomised in the ICS 
treatment arm, improved clinically with a decrease in ACQ7 of ≥0.5 and were over twice as 
likely to show clinical improvement in ACQ7 compared to those who did receive additional 
treatment. We found that there was a greater proportion of patients with normal FeNO values 
that spontaneously improved compared to those with intermediate or high FeNO. This was 
likely due to a higher proportion of patients presenting with normal FeNO not suffering from 
asthma. Although further diagnostics beyond the clinical history and baseline study 
procedures were not carried out during this study to confirm or exclude an asthma diagnosis, 
clinical judgement of diagnosis was completely non-predictive of response to ICS versus 
placebo. 
The study population had relatively low levels of symptom severity as measured by ACQ7, 
which may have influenced the magnitude of the interaction effect of FeNO and treatment on 
change in ACQ7. This is likely a result of the requirement of no bronchodilator reversibility (< 
20%) in the study criteria. None of the patients in our study had a reversibility of FEV1 more 
than 19.35%, which is lower than the validated limits as stated by the ATS/ERS guidelines. 
(23) The sample did not comprise of patients with a pre-existing history of asthma, for which 
the use of ACQ7 is recommended. In a population with mild or few symptoms, it can be difficult 
to show improvement in symptoms. Thus, the assay sensitivity of the trial, i.e. its ability to 
detect effectiveness, may be reduced.(24) The presence of mild symptoms in the study 
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population was also thought to be a limiting factor in the study by Smith et al,(15) in which a 
large proportion of patients with high FeNO did not respond to treatment. It is therefore likely 
that ACQ7 is not an optimal measure of responsiveness in this population.  
We observed that the proportion of male subjects increased in the high FeNO strata. This has 
been previously reported. Multiple studies have found that FeNO levels are statistically 
significantly higher in males.(25-28) However, the observed changes were not clinically 
relevant with changes ranging between 1 and 2-fold.(27) The reason for this association still 
remains unclear and has not been shown to be influenced by differences in height, vital 
capacity, or total lung capacity. Future study into whether the observed differences between 
genders affect the utility of FeNO as a tool for response to therapy will increase accuracy of 
prescription. 
Previous studies have demonstrated that blood eosinophil counts and FeNO offer 
independent information for the diagnosis of respiratory symptoms (29). Our data show that 
patients with increasing blood eosinophil counts behave in a similar manner to those with 
increasing FeNO levels. However, this is an exploratory analysis and further study is needed 
to confirm the value of combining blood eosinophil counts and FeNO in predicting the 
response to ICS. 
To our knowledge, this is one of the first well-controlled studies investigating the value of FeNO 
measurement for guiding ICS treatment in a difficult-to-manage patient population with 
unspecific symptoms. The strengths of this study include its rigorous study design, i.e. 
randomised, double-blind and placebo controlled, as well as taking place in multiple centres. 
The study included a treatment period of four weeks, which meets previous recommendations 
in patients with asthma.(30) The study objectives addressed a patient population that is 
notably difficult to treat in real-life practice, and for which there is a need for more clinical 
evidence to guide treatment strategies. Its outcome measures were variables that can be 
easily measured in routine primary care – FeNO, spirometry and peripheral blood eosinophils 
- and so its findings are widely implementable. Although the number of patients randomised 
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exceeded the target sample size to achieve 80% power, a limitation of this study is that the 
size of the Per-Protocol set fell just below this target. Patients were excluded from the Per-
Protocol analysis mainly because the study visits fell outside the study window. This meant 
they were no longer taking the assigned treatment thus potentially altering the data collected. 
The exploratory analysis - which was carried out in the treatment arm only - is particularly 
affected by reduced power, but the hypotheses generated, concerning the comparison of 
FeNO and other predictive measures, are valuable for further study.   
In terms of clinical practicality and implications, FeNO is a simple and non-invasive tool that 
can be easily be implemented in routine primary care. The findings of this study suggest that 
patients with non-specific respiratory symptoms (but no obvious asthma), insignificant 
bronchodilator reversibility and low FeNO are not likely to respond to ICS and so this treatment 
could be avoided. ICS are being over prescribed, in recent years regulatory bodies and 
guidelines have emphasised reducing ICS use where possible. The use of FeNO as a 
predictor of response to ICS could be an additional tool for health care professionals to 
optimise patient care. This is a vital implication: once ICS has been initiated, a patient with 
mild symptoms may appear to have well-controlled disease due to ICS and therefore are 
unnecessarily exposed to long-term ICS treatment.(31) Clearly, such inappropriate treatment 
comes at an unnecessary cost and exposes the patient to the potential long-term adverse 
effects of ICS.(32)  
The results of this study also raise a question about what patients mean when they refer to 
cough or other respiratory symptoms. One previous study examined the use of the word 
wheeze, demonstrating that it was often cough and other symptoms.(33) It also demonstrated 
a clear mismatch between doctors and patients concerning the use of these words. 
Our findings showed FeNO to have more potential in guiding treatment than either spirometry 
or eosinophils, although eosinophils were also predictive prior to adjustment by FeNO. 
Meanwhile, clinical opinion of whether the patient was asthmatic had no relationship with 
treatment response. This data helps to move forward the research in this difficult-to-manage 
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patient population, and with future studies the findings could lead to stronger and refined 
recommendations for how to manage these patients. Future studies may include more 
potential predictors, such as a comparison between FeNO and airway hyperresponsiveness 
– measured often in secondary care – and measurement of outcomes following an extended 
treatment period beyond 4 weeks. 
Conclusion 
FeNO measurement is a simple, non-invasive diagnostic tool that could have a valuable role 
in identifying a subpopulation of patients with non-specific respiratory symptoms, such as 
cough, wheeze and shortness of breath, who may benefit from ICS therapy. Our exploratory 
research suggests FeNO measurement at baseline may be more valuable than spirometry, 
peripheral blood eosinophils or clinical judgement in predicting treatment response to ICS. 
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Figures and Tables  
Table 1. Baseline characteristics of Per-Protocol set, by treatment arm 
Baseline study measure 
 Mean (SD) for continuous variables; n (%) for categorical variables* 
Extrafine ICS (N=114) Placebo (N=100) 
Age (yrs) 50.0 (15.5) 47.7 (17.0) 
Body Mass Index (kg/m2) 27.6 (5.2) 27.6 (6.0) 
Female 60 (52.6%) 63 (63.0%) 
Smoking status     
     Current Smoker   11 (9.6%)    1 (1.0%) 
     Ex-Smoker   30 (26.3%)   26 (26.0%) 
     Never-Smoker   73 (64.0%)   73 (73.0%) 
Country     
UK   80 (70.2%)   78 (78.0%) 
     Singapore   34 (29.8%)   22 (22.0%) 
FeNO (ppb) 36.1 (27.2) 39.6 (31.5) 
ACQ7† 1.61 (0.57) 1.71 (0.6) 
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FEV1 (L) 2.78 (0.92) 2.81 (0.82) 
FEV1 (%predicted) 90.8 (16.5) 92.9 (14.9) 
FVC (L) 3.59 (1.17) 3.61 (1.11) 
FVC (%predicted) 95.4 (18.8) 97.7 (16.3) 
FEV1/FVC (%) 0.78 (0.09) 0.79 (0.09) 
PEF (L/min) 222.5 (233.4) 261.11 (209.4) 
EuroQol 5 Dimensions 
Questionnaire 0.85 (0.17) 0.87 (0.13) 
VAS Cough (mm) 42.0 (29.1) 41.1 (26.6) 
VAS Symptom (mm) 46.5 (25.6) 46.7 (26.3) 
Eosinophil count (10E9/L) 0.2 (0.27) 0.2 (0.15) 
Reversibility score‡ (%) 2.37 (0.84) 2.47 (0.74) 
Clinical judgement: patient is 
asthmatic   62 (54.9%)   60 (60.6%) 
Clinical judgement: treatment is 
clinically justified  113 (100.0%)§   99 (100.0%)§ 
Probable COPD¶ 2 (1.8%) 2 (2.0%) 
*Variables were compared between treatment arms using Mann Whitney U tests for continuous 
variables, and Chi-squared tests for categorical variables. A significant difference was observed for 
smoking status (P = 0.021). † ACQ7 recorded at either Visit 1 or Visit 2 of the study – original procedure 
was to collect at visit 2, but as many patients were found not to be eligible in terms of ACQ7, the protocol 
was changed to collect the baseline ACQ7 at visit 1, for efficiency. All other baseline measurements 
were taken at Visit 1. ‡Reversibility scores calculated for patients with no record of reversibility in 
previous year (51 patients in extrafine ICS arm; 37 patients in placebo arm). Formula for reversibility: 
(FEV1 post-salbutamol minus FEV1 pre-salbutamol)*100. §One patient in each arm had missing data 
for the clinical judgement questions. ¶Criteria: current/ex-smoker AND FEV1 % Predicted<80% AND 
FEV1/FVC<0.7. ICS=inhaled corticosteroids; SD=standard deviation; FeNO=fractional exhaled nitric 
oxide; ACQ7=asthma control questionnaire, 7 questions; FEV1=forced expiratory volume in first second; 
FVC=forced vital capacity; PEF=peak expiratory flow; EQ-5D-3L=EuroQol 5 Dimensions 
Questionnaire; VAS=visual analogue scale. 
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Figure 1. CONSORT flow diagram of study participation  
 
 
ICS=inhaled corticosteroids 
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Table 2. Primary analysis: change in ACQ7 by treatment arm and baseline FeNO 
Measurement  
Extrafine 
ICS 
(N=114) 
Placebo 
(N=100) 
Adjusted treatment effect* 
(extrafine ICS minus placebo) / 
Interaction effect with FeNO† 
Mean (SD) change in ACQ7 (follow-up 
minus baseline):     
Total (n=214) 0.82 (0.70) 
0.56 
(0.78) 0.29 (0.08, 0.49) 
Normal FeNO‡ (n=77) 0.80 (0.59) 
0.73 
(0.62) 0.10 (-0.24, 0.44) 
Intermediate FeNO‡ (n=68) 0.70 (0.75) 
0.47 
(0.89) 0.25 (-0.10, 0.61) 
High FeNO‡ (n=69) 0.97 (0.77) 
0.49 
(0.78) 0.49 (0.14, 0.84) 
Interaction effect:     
Difference (95% CI) in treatment effect† 
for every 10ppb increase in baseline 
FeNO    0.071 (0.002, 0.139) ¶ 
SENSITIVITY ANALYSIS    
Difference in Gradients (Extrafine ICS - 
Placebo)   0.045 (0.006, 0.084)≠ 
 
*All models adjusted by baseline FeNO and smoking status. †Difference in treatment effect is interpreted 
as the additional change in continuous outcome in the extrafine ICS versus placebo arm when baseline 
FeNO is 10 ppb higher. ‡Normal, ≤25 ppb; Intermediate, >25 ppb - <40 ppb; High, ≥40 ppb. ¶P 
value=0.044; Significant p values indicate a significant interaction, i.e. baseline FeNO is associated with 
the size of the treatment response. CI=confidence interval; FeNO=fractional exhaled nitric oxide; 
ACQ7=asthma control questionnaire, 6 questions and FEV1. ≠A negative value indicates lower 
improvement in outcome as FeNO increases for Extrafine ICS compared to Placebo. 
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Table 3 Patients with improvement in ACQ (≥0.5) 
 
 
 
 
 
 
 
 
 
 
 
Change in ACQ 
(Per-protocol population) 
  
Normal 
(n=77) 
  
Intermediate 
(n=68) 
  
High 
(n=69) 
 
Total 
(n=214) 
  
Extra Fine ICS 
        (n=45) 
Placebo 
(n=32) 
Extra Fine ICS 
 (n=33) 
Placebo 
(n=35) 
Extra Fine ICS 
(n=36) 
Placebo 
(n=33) 
Extra Fine ICS 
(n=114) 
Placebo 
(n=100) 
Clinical improvement (≥0.5)* 32 (71.1%) 22 (68.8%) 21 (63.6%) 18 (51.4%) 27 (75.0%) 18 (54.6%) 80 (70.2%) 58 (58.0%) 
No clinically important change 
(<0.5 and ≥-0.5) 
13 (28.9%) 9 (28.1%) 8 (24.24%) 11 (31.4%) 9 (25.0%) 11 (33.33%) 30 (26.3%) 31 (31.0%) 
Clinical deterioration (<-0.5) 0 (0.0%) 1 (3.1%) 4 (12.12%) 6 (17.1%) 0 (0.0%) 4 (12.12%) 4 (3.5%) 11 (11.0%) 
Number-needed-to-treat (NNT) 58.82 33.33 17.24 34.42 
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Table 4. Primary analysis: change in ACQ6 by treatment arm and baseline FeNO 
 
Extrafine ICS 
(n=114) 
Placebo 
(n=100) 
Total 
(n=214) 
Estimates from Model 
(95% CI) P-value 
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Extrafine ICS 
(n=114) 
Placebo 
(n=100) 
Total 
(n=214) 
Estimates from Model 
(95% CI) P-value 
Per-Protocol Set 
n (% non-missing)                            114 (83.2%) 100 (82.0%) 214 (82.6%) 
  
Mean (SD)                                        0.93 (0.81) 0.65 (0.90) 0.80 (0.86) 0.29 (0.08, 0.49) ‡ 
 
Median (IQR)                                  0.8 (0.5, 1.5) 0.8 (0.1, 1.2) 0.8 (0.3, 1.3) 
  
Min, Max                                          -1.0, 4.2 -1.7, 2.7 -1.7, 4.2 
  
Estimated change in ACQ improvement when baseline FeNO is 10ppb higher 
Extrafine ICS                                     
   
0.053 (-0.005, 0.112) 
 
Placebo                                           
   
-0.022 (-0.076, 0.031) 
 
Difference in Gradients (Extrafine ICS - Placebo) 
   
0.076 (-0.004, 0.155) *  0.061 
 30 
 
 
Extrafine ICS 
(n=114) 
Placebo 
(n=100) 
Total 
(n=214) 
Estimates from Model 
(95% CI) P-value 
‡: The difference in mean change of outcome between Extrafine ICS and Placebo (Extrafine ICS - Placebo) after adjustment for FeNO and smoking status. 
*: A positive value indicates greater improvement in outcome as FeNO increases for Extrafine ICS compared to Placebo. 
 
Table 5. Interaction effects - between baseline FeNO and treatment arm - on the association between treatment and change in secondary outcomes 
Outcome analysed (change from 
baseline to follow-up)* 
Mean (SD) change in outcome 
Difference (95% CI) in treatment effect† for every 10 
ppb increase in baseline FeNO  P value‡ Extrafine ICS Placebo 
VAS Cough 18.69 (30.02) 11.83 (28.67) 3.406 (0.707, 6.105) 0.014 
VAS Symptom 22.04 (30.21) 15.05 (29.09) 2.125 (-0.644, 4.895) 0.132 
FEV1 (L) 0.05 (0.18) 0.03 (0.16) 0.021 (0.005, 0.036) 0.010 
FEV1 (% predicted) 1.93 (7.50) 0.73 (5.83) 0.552 (-0.035, 1.139) 0.065 
FVC (L) 0.05 (0.23) 0.06 (0.21) 0.013 (-0.008, 0.034) 0.229 
FVC (% predicted) 1.76 (8.20) 1.82 (7.90) 0.177 (-0.540, 0.893) 0.627 
FEV1/FVC (%) 0.00 (0.04) -0.01 (0.04) 0.002 (-0.002, 0.006) 0.273 
PEF (% predicted) 4.05 (12.90) 2.43 (10.76) 0.571 (-0.482, 1.624) 0.286 
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*Models adjusted by baseline FeNO and smoking status. †Difference in treatment effect is interpreted as the additional change in continuous outcome in the 
extrafine ICS versus placebo arm when baseline FeNO is 10 ppb higher. ‡Significant p values indicate a significant interaction, i.e. baseline FeNO is associated 
with the size of the treatment response. CI=confidence interval; FeNO=fractional exhaled nitric oxide; FEV1=forced expiratory volume in first second; 
FVC=forced vital capacity; PEF=peak expiratory flow. VAS=visual analogue scale. Severity of Cough (VAS) was measured on a 0-100 vertical visual analogue 
scale for severity of cough 0 (no cough) 100 (worse cough ever). Perception of Asthma symptoms (VAS) was measured on a 0-100 horizontal visual analogue 
scale for how bothersome they find their asthma 0 (not at all bothersome) 100 (extremely bothersome). 
Table 6. Summary of adverse events during the study, in all randomised patients (n=294) 
Summary measure 
Extrafine ICS Placebo 
  
Normal FeNO* 
(n=56) 
Intermediate 
FeNO* (n=44) 
High FeNO* 
(n=48) 
Normal FeNO* 
(n=51) 
Intermediate 
FeNO* (n=48) 
High FeNO* 
(n=47) 
Extrafine ICS 
(n=148) 
Placebo (n=146) 
Number of patients 
with at least 1 adverse 
event   13 (23.2%)   15 (34.1%)   19 (39.6%)   17 (33.3%)   18 (37.5%)   20 (42.6%)   47 (31.8%)   55 (37.7%) 
Number of adverse 
events, by severity†         
Mild 12 19 17 14 19 20 48 53 
Moderate 3 3 13 10 10 10 19 30 
Severe 0 0 0 0 0 2 0 2 
Total 15 22 30 24 29 32 67 85 
Number of adverse 
events due to 
treatment 0 4 5 4 8 3 9 15 
Number of adverse 
events causing 
discontinuation of 
study drug 0 0 3 6 2 9 3 17 
*Normal baseline FeNO: ≤25-; Intermediate baseline FeNO: >25 - <40 ppb; High baseline FeNO: ≥40 ppb. †Mild: No limitation of usual activities; Moderate: 
some limitation of usual activities; Severe; Inability to carry out usual activities 
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Figure 2. Predictors of clinical response in ACQ7 and VAS cough, in the extrafine ICS arm of the exploratory analysis set (n=137) 
 
*Clinical improvement defined as decrease ≥ 0.5 for ACQ7, and decrease ≥ 20mm for VAS Cough.  †All variables, except continuous FeNO and FEV1 % 
Predicted, are binary. The reference category for odds ratios is the opposite category of what is presented, e.g. odds for patients reporting no dyspnoea 
symptoms are compared with odds for patients who did report dyspnoea symptoms. Odds ratio for continuous FeNO represents the increase in odds for every 
10 ppb increase in baseline FeNO. ‡Additional treatment defined as any treatment received for non-specific respiratory symptoms at study enrolment, apart 
from extrafine ICS or any treatment listed in the exclusion criteria. Bold text indicates significant association. CI=confidence interval; FeNO=fractional exhaled 
nitric oxide; VAS=visual analogue scale. 
